EF-5 NEW
| Price | $43 | $73 | $148 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: EF-5 | CAS No.: 152721-37-4 |
| Purity: 98.26% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | EF-5 |
| Description | EF-5 (2-Nitroimidazole) is a agent of hypoxia labeling. It is used to identify hypoxia in cells. |
| In vitro | EF-5 binding and metabolic reduction of the prodrugs are highly correlated in a panel of 14 hypoxic tumor cell lines. Overexpression of CYPOR causes similar 2- to 4-fold increases in EF-5 binding and metabolic reduction of tirapazamine and CEN-209 in SiHa and HCT116 cell lines. Which is similar enhancement of γH2AX formation.[1]. |
| In vivo | EF-5 binding is a promising stratification biomarker for benzotriazine-N-oxide bioreductive prodrugs. Binding and detection using a monoclonal antibody in 9L gliomas is specific and oxygen-dependent after intravenous injection of EF-5. Tumor hypoxia modification causes similar changes in the bioreductive activation of both agents, showing a strong correlation between EF-5 binding and CEN209-induced DNA damage at the individual tumor level [1]. Detection using fluorescence microscopy can be performed on frozen tissues, with tissue sections counterstained with haematoxylin and eosin for light microscopic analysis. The hypoxia distribution in a tumor can be inferred by examining individual tumor cells using flow cytometric techniques [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 125 mg/mL (413.69 mM), Sonication is recommended. |
| Keywords | inhibit | EF-5 | EF 5 | Inhibitor |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | NO PAINS Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1520.00/25mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $1.00/2kg |
ARCTIC EXPORTS INC
|
2024-01-05 | ||
| $200.00/1kg |
VIP1Y
|
Hebei Zhuanglai Chemical Trading Co.,Ltd
|
2024-04-25 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY